John Giblin: Influence Statistics

John Giblin

John Giblin

From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals ...

John Giblin: Expert Impact

Concepts for which John Giblin has direct influence: Lisdexamfetamine dimesylate , Oros methylphenidate , Ldx adults , Lisdexamfetamine dimesylate ldx , Crossover study , Lisdexamfetamine dimesylate adults , Adults adhd .

John Giblin: KOL impact

Concepts related to the work of other authors for which for which John Giblin has influence: Lisdexamfetamine dimesylate , Hyperactivity disorder , Adults adhd , Attention deficit , Children adolescents , School performance , College students .

KOL Resume for John Giblin

Year
2012

From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Centers, LLC, Little Rock, AR; ∥Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV; ¶Biostatistics, US Medical; and #Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

2011

Clinical Study Centers, LLC, Little Rock, AK, USA

2010

Clinical Study Centers, LLC, Little Rock, AR, USA

Prominent publications by John Giblin

KOL-Index: 16541 . BACKGROUND: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment. METHODS: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subjects entered a 2-week randomized, double-blind, placebo-controlled crossover phase. Efficacy ...
Known for Lisdexamfetamine Dimesylate | Ldx Adults | Hyperactivity Disorder | Crossover Study
KOL-Index: 10241 . Background: Long-acting methylphenidate formulations provide control of attention-deficit hyperactivity disorder (ADHD) symptoms for up to 12 hours; however, not all formulations have rapid onset of therapeutic effect, which is essential for providing symptom control during morning hours. The primary objective of this randomized, double-blind, crossover study was to assess the efficacy of ...
Known for Hyperactivity Disorder | Crossover Study | Daily Dexmethylphenidate | Post Dose
KOL-Index: 9425 . OBJECTIVE: To examine duration of efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/hyperactivity disorder (ADHD) by effect size in performance and symptom improvement in a simulated adult workplace environment (AWE). METHODS: Adults (aged 18-55 years) with ADHD enrolled in the AWE study of LDX with open-label dose-optimization and randomized, ...
Known for Lisdexamfetamine Dimesylate | Hyperactivity Disorder | Adults Adhd | Adult Attention
KOL-Index: 8635 . OBJECTIVE: To assess improvements in quality of life measurements during the open-label portion of a trial examining duration of efficacy of lisdexamfetamine dimesylate in a simulated adult workplace environment. METHODS: A 4-week, open-label, dose-optimization phase followed by a randomized, double-blind, multicenter, placebo-controlled, 2-way crossover phase to evaluate safety and ...
Known for Lisdexamfetamine Dimesylate | Life Adults | Reported Quality | Attention Deficit
KOL-Index: 7485 . OBJECTIVE: To assess effects of OROS methylphenidate on cognitive and academic tasks in 9 to 12 year olds with attention-deficit/hyperactivity disorder (ADHD). METHODS: A double-blind, within-subject, crossover design was used to compare OROS methylphenidate with placebo in a laboratory classroom setting on several cognitive and academic tasks for 68 children who met randomization ...
Known for Oros Methylphenidate | Cognitive Tasks | Hyperactivity Disorder | Attention Deficit
KOL-Index: 7256 . The objective of this study was to evaluate the safety and efficacy of dexmethylphenidate extended-release (d-MPH-ER) 30 versus 20 mg in children with attention-deficit/hyperactivity disorder (ADHD) in a 12-hour laboratory classroom setting. In a randomized, double-blind, 3-period × 3-treatment, crossover study, children aged 6 to 12 years with Diagnostic and Statistical Manual of Mental ...
Known for Hyperactivity Disorder | 30 Mph | Versus 20 | Attention Deficit
KOL-Index: 3636 . Background and Objective: The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD). The studies described in this manuscript were conducted to fulfil the requirements of the paediatric written request for pantoprazole by the US ...
Known for Reflux Disease | Infants Children | Proton Pump | Gastro Oesophageal

Key People For Lisdexamfetamine Dimesylate

Top KOLs in the world
#1
JOSEPH Biederman
bipolar disorder attention deficit adults adhd
#2
Suma Krishnan
lisdexamfetamine dimesylate children adhd hyperactivity disorder
#3
Yuxin Zhang
lisdexamfetamine dimesylate adderall xr plasma concentrations
#4
Ann Catherine Childress
hyperactivity disorder lisdexamfetamine dimesylate aptensio xr
#5
Lenard A Adler
adult adhd hyperactivity disorder lisdexamfetamine dimesylate
#6
Stephen V Faraone∗
hyperactivity disorder attention deficit children adhd

From the &amp;ast;Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Ce